Berto Acquisition Corp.

# Signal Note: Driehaus Initiates SPAC Position Driehaus Capital's $84K entry into Berto Acquisition Corp. signals conviction in an undisclosed biotech target; the SPAC's blank-check status requires monitoring SEC filings for merger announcement details, which will clarify therapeutic focus and clinical/commercial stage. Growth-focused allocators typically target SPACs with near-term catalysts (Phase 2/3 data, regulatory decisions) or differentiated mechanisms, making deal disclosure the critical inflection point for assessing risk/reward alignment with the fund's biotech thesis.